Caldera Reports Positive CLD-423 Phase 1a Data, Adds IL-17 x TL1A License Ahead of Synlogic Merger
SYBX sits 85% above its 52-week low of $0.54.
Summary
Caldera, the private company merging with Synlogic, released positive interim Phase 1a data for its lead bispecific antibody CLD-423, licensed a second IL-17 x TL1A program from Qyuns, and reiterated an upsized ~$278 million concurrent private placement. The merger is still awaiting an effective S-4 and stockholder votes, with closing expected in early 2027.
Key Events · M&A and Partnerships · SYBX
-
CLD-423 Phase 1a Data Positive
Interim analysis covering the fifth single-dose cohort and both multiple-dose cohorts showed no dose-limiting toxicities, mostly Grade 1 adverse events, an IV half-life above 40 days and approximately 89% subcutaneous bioavailability, with sustained TL1A suppression.
-
Phase 2 IBD Trials Planned for 2027
Caldera plans a Phase 2b ulcerative colitis trial (IND in Q4 2026, first patient early 2027, induction results by end of 2028) and a Phase 2a Crohn's trial in China (first patient early 2027, initial data late 2027).
-
Qyuns IL-17 x TL1A License Added
An exclusive worldwide development and commercialization license with Qyuns Therapeutics (HKEX 2509.HK) adds a preclinical bispecific antibody program targeting IL-17 and TL1A; financial terms were not disclosed.
-
Placement Upsized to ~$278M
Caldera has commitments for an upsized concurrent private placement expected to generate approximately $278 million in gross proceeds from healthcare institutional investors and mutual funds.
Analysis · SYBX · Life Sciences
Synlogic shareholders are being asked to approve an all-stock merger that leaves them with only 2.3% of the combined company, so the value of their stub equity depends almost entirely on Caldera's pipeline. This filing delivers the first substantive clinical update since the deal was struck: CLD-423 was generally well tolerated with no dose-limiting toxicities, showed a half-life above 40 days and roughly 89% subcutaneous bioavailability, and sustained TL1A suppression — enough for Caldera to commit to a Phase 2b ulcerative colitis trial and a Phase 2a Crohn's trial starting in 2027. The Qyuns license adds a second, preclinical bispecific asset at no disclosed cost. The concurrent private placement is now described as upsized to about $278 million, which funds the combined company through those trials. The remaining hurdle is the S-4 registration statement, which has not yet been declared effective, plus stockholder votes at both companies; closing is expected in early 2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SYBX was trading at $1.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $12.2M. The 52-week trading range was $0.54 to $1.87. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.